IP Library › Granted Patent US 8,664,276
Granted Patent B2
US 8,664,276 · App. 13/360,109 · Granted Mar 4, 2014

Stilbene analogs and methods of treating cancer

Inventors: David Watt (Lexington, KY); Chunming Liu (Lexington, KY); Vitaliy M. Sviripa (Lexington, KY); Wen Zhang (Lexington, KY)
Assignee: University of Kentucky Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,276
App. No.
13/360,109
Granted
Mar 4, 2014
Kind
B2
Abstract

Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. Such stilbene analogs include, for example, compounds of the following formula: wherein R a , R b , R 4 , R 6 , R 7 , R 9 and R 10 are all H; R 2 and R 3 are independently H, halo, amino, alkylamino, dialkylamino, N-oxides of dialkylamino, arylalkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, CONR 11 R 12 , NR 11 CO(R 13 ), NR 11 COO(R 13 ) or NR 11 CONR 12 R 13 ; R 11 , R 12 and R 13 , are independently, H, alkyl, aryl, heteroaryl or a fluorine; R 8 is NR C R d Z wherein R c is H, alkyl, alkoxy, aryl or heteroaryl, R d is an alkyl group, Z is a an unshared pair of electrons, H, alkyl or oxygen; and R 1 and R 5 are halogen.

Claims (16)

1. A compound according to formula (II):

or a pharmaceutically acceptable salt thereof, wherein R a , R b , R 4 , R 6 , R 7 , R 9 , R 10 are all H; R 2 and R 3 are independently H, halo, amino, alkylamino, dialkylamino, N-oxides of dialkylamino, arylalkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, CONR 11 R 12 , NR 11 CO(R 13 ), NR 11 COO(R 13 ), NR 11 CONR 12 R 13 ; R 11 , R 12 and R 13 , are independently, H, alkyl, aryl, heteroaryl or a fluorine; R 8 is NR c R d Z wherein R c is H, alkyl, alkoxy, aryl, heteroaryl, R d is an alkyl group, Z is a an unshared pair of electrons, H, alkyl, oxygen; and R 1 and R 5 are halogen.

2. The compound according to claim 1 , wherein the compound is selected from the group consisting of (E)-4-(2,6-Difluorostyryl)-N,N-dimethylaniline; (E)-4-(2,6-Difluorostyryl)-N,N-diethylaniline; (E)-4-(2-chloro-6-fluorostyryl)-N,N-dimethylaniline; (E)-4-(2,6-dichlorostyryl) -N,N-dimethylaniline; (E)-4-(2,6-difluorostyryl)-N-methylaniline; (E)-4-(2-chloro-6-fluorostyryl)-N-methylaniline; (E and Z)-4-(2,6-dichlorostyryl)-N-methylaniline; (E)-4-(2,6-difluorostyryl)-N,N,N-trimethylbenzenammonium iodide; and

pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 , wherein Z is O.

4. The compound according to claim 3 , wherein the compound is selected from the group consisting of (E)-4-(2,6-difluorostyryl)-N,N-dimethylaniline oxide; (E)-4-(2-chloro-6-fluorostyryl)-N,N-dimethylaniline oxide; (E)-4-(2,6-dichlorostyryl)-N,N-dimethylaniline oxide.

5. A composition comprising a compound according to formula (II):

or a pharmaceutically acceptable salt thereof, wherein R a , R b , R 4 , R 6 , R 7 R 9 , R 10 are all H; R 2 and R 3 are independently H, halo, amino, alkylamino, dialkylamino, N-oxides of dialkylamino, arylalkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, CONR 11 R 12 , NR 11 CO(R 13 ), NR 11 COO(R 13 ), NR 11 CONR 12 R 13 ; R 11 , R 12 and R 13 , are independently, H, alkyl, aryl, heteroaryl or a fluorine; R 8 is NR c R d Z wherein R c is H, alkyl, alkoxy, aryl, heteroaryl, R d is an alkyl group, Z is a an unshared pair of electrons, H, alkyl, oxygen; and R 1 and R 5 are halogen; and a pharmaceutically acceptable carrier.

6. The composition of claim 5 , wherein R 1 and R 5 are independently a chlorine or fluorine.

7. The composition according to claim 5 , wherein R 1 and R 5 are fluorine substituents and R d is lower alkyl group.

8. The composition of claim 5 , wherein R 1 is chlorine and R 5 is fluorine.

9. The composition of claim 5 , wherein R c is H or alkyl, R d is a lower alkyl group, and Z is a an unshared pair of electrons.

10. The compound of claim 1 , wherein R 1 and R 5 are independently a chlorine or fluorine.

11. The compound of claim 1 , wherein R 1 is chlorine and R 5 is fluorine.

12. The compound of claim 1 , wherein R c is H or alkyl, R d is a lower alkyl group, and Z is a an unshared pair of electrons.

13. The compound of claim 10 , wherein R c is H or alkyl, R d is a lower alkyl group, and Z is a an unshared pair of electrons.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2012
From: WATT, DAVID; LIU, CHUNMING; SVIRIPA, VITALIY M.; ZHANG, WEN
To: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Reel/Frame 028053/0544 →
Continuity (3)
Provisional Application 61437341 · Jan 28, 2011
Provisional Application 61439118 · Feb 3, 2011
Related Publication 20120196874A1 · Aug 2, 2012